#riskbasedmonitoring

Zenovel’s Risk-Based Monitoring (RBM) services focus on identifying critical risks, enhancing data integrity, and ensuring patient safety through a combination of centralized and on-site monitoring approaches—aligned with global regulatory expectations.

Risk-based monitoring is the process of ensuring the quality of clinical trials by identifying, assessing, monitoring, and mitigating risks that may have an impact on the study's quality or safety.

The decrease in the cost of clinical trials is a major factor that will drive the growth of the Risk-based Monitoring Market during the forecast period. Clinical trials are expensive during drug development, and it is estimated that risk-based monitoring can cut clinical trial costs by 30%. The risk-based monitoring process, in comparison to traditional studies, reduces clinical data error, which may drive the risk-based monitoring market growth during the forecast period. For example, the Association of Clinical Research Organizations (ACRO) is urging the FDA in 2019 to place even more emphasis on risk-based monitoring (RBM) of clinical trials, citing a recent study of its members that revealed a 16% reduction in major findings in audits among sites using this method.